Chemical renal denervation for the treatment of resistant hypertensio
- Conditions
- I10.9
- Registration Number
- DRKS00008746
- Lead Sponsor
- Klinikum der Universität München, Campus Großhadern
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
• Patient with therapy-resistant type. Hypertonicity (syst. RR> 140 mmHg despite optimized therapy with = 3 antihypertensive drugs of different classes - state of the art over 3 months),
• Diagnosis of the therapy-resistant type. Hypertension by a specialist in nephrology / high-pressure ambulance takes place incl. Advice on all alternative therapy methods
• GFR> 45 ml / min / 1.73 m²
Pat. With refractory hypertension at Z.n. ineffective catheter-directed RD
• patients with secondary hypertension (e.g., renoparenchymatous hypertension, NAST, primary hyperaldosteronism, pheochromocytoma, sleep apnea syndrome)
• Stenosing heart valve disease
• Z.n. Myocardial infarction, unstable angina pectoris, cerebrovascular event within the last 6 months prior to enrollment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The procedure leads to a permanent lowering of blood pressure compared to the control group (state of the art antihypertensive medication plus sham treatment).
- Secondary Outcome Measures
Name Time Method • Permanent reduction of antihypertensive medication in patients with refractory hypertension compared to sham control<br>• Compared to catheter-guided radiofrequency ablation, the procedure is simpler, faster, less expensive, and feasible for patients with a contraindication to RFA.